Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 18/20 | 1.00 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20476786 | 0.83 | TXNRD1 (1.00) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL22280583 | 0.81 | TXNRD1 (1.00) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL20476865 | 0.80 | TXNRD1 (1.00) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL22280432 | 0.80 | TXNRD1 (1.00) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL20471813 | 0.78 | TXNRD1 (0.75) | TXNRD1 | |
| SCHEMBL22280413 | 0.78 | TXNRD1 (1.00) | TXNRD1S1PR4MAPTS1PR1MAPK1 | |
| SCHEMBL20471816 | 0.77 | TXNRD1 (1.00) | TXNRD1 | |
| SCHEMBL20471809 | 0.77 | TXNRD1 (1.00) | TXNRD1 | |
| SCHEMBL28475719 | 0.77 | TXNRD1 (0.73) | TXNRD1 | |
| SCHEMBL22280409 | 0.76 | TXNRD1 (1.00) | TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2022-04-21 | — | — | US | disclosed |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-02 | — | — | US | disclosed |
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | OBLIQUE THERAPEUTICS AB (SE) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239417-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | TXNRD1 549/4885S1PR4 919/4885MAPT 4656/4885 |
| US-20220119348-A1 | HYDROCARBYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN THE TREATMENT OF CANCER | HCCS, ABL1, IDH1 | TXNRD1 549/4885S1PR4 919/4885MAPT 4656/4885 |
| US-11161815-B2 | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | HCCS, ABL1, IDH1 | TXNRD1 549/4885S1PR4 919/4885MAPT 4656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.